Furthermore, our data support the notion that a pharmaceutical drug-inhibiting Akt activity may not be sufficient to kill cancer cells on its own, but may be used to lower the apoptotic threshold and to resensitise chemoresistant tumours in combination treatment with defined chemotherapeutic drugs. Here, AKT1 is linked to neoplasm.